

# Dipeptide Peptidase 4 Inhibitors Market Size, Trends, Analysis, and Outlook By Drugs (Januvia (Sitagliptin), Onglyza (Saxagliptin), Tradjenta (Linagliptin), Vipidia (Alogliptin), Galvus (Vildagliptin), Others), by Region, Country, Segment, and Companies, 2024-2030

<https://marketpublishers.com/r/DD60F85057BBEN.html>

Date: March 2024

Pages: 190

Price: US\$ 3,980.00 (Single User License)

ID: DD60F85057BBEN

## Abstracts

The global Dipeptide Peptidase 4 Inhibitors market size is poised to register 2.88% growth from 2024 to 2030, presenting significant growth prospects for companies operating in the industry. The industry study analyzes the global Dipeptide Peptidase 4 Inhibitors market across By Drugs (Januvia (Sitagliptin), Onglyza (Saxagliptin), Tradjenta (Linagliptin), Vipidia (Alogliptin), Galvus (Vildagliptin), Others).

The dipeptide peptidase 4 (DPP-4) inhibitors market is experiencing steady growth driven by the rising prevalence of type 2 diabetes and the increasing demand for effective glucose-lowering medications with favorable safety profiles. DPP-4 inhibitors, also known as gliptins, are oral antidiabetic drugs that work by inhibiting the enzyme DPP-4, thereby increasing the levels of incretin hormones and improving glycemic control in patients with diabetes. Factors such as the growing awareness about the importance of early diabetes management, the emphasis on personalized treatment approaches, and the introduction of novel DPP-4 inhibitors with improved efficacy and tolerability are driving market growth. Additionally, the rising adoption of combination therapies, including DPP-4 inhibitors in fixed-dose combinations with other antidiabetic agents, is expanding the market opportunities for DPP-4 inhibitors. Moreover, the availability of generic versions of DPP-4 inhibitors, patent expiries, and healthcare reforms aimed at improving access to affordable diabetes medications are further contributing to market expansion, especially in emerging economies.

Dipeptide Peptidase 4 Inhibitors Market Drivers, Trends, Opportunities, and Growth

*Dipeptide Peptidase 4 Inhibitors Market Size, Trends, Analysis, and Outlook By Drugs (Januvia (Sitagliptin), O...*

## Opportunities

This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Dipeptide Peptidase 4 Inhibitors market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Dipeptide Peptidase 4 Inhibitors survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Dipeptide Peptidase 4 Inhibitors industry.

### Key market trends defining the global Dipeptide Peptidase 4 Inhibitors demand in 2024 and Beyond

The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.

### Dipeptide Peptidase 4 Inhibitors Market Segmentation- Industry Share, Market Size, and Outlook to 2030

The Dipeptide Peptidase 4 Inhibitors industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Dipeptide Peptidase 4 Inhibitors companies scaling up production in these sub-segments with a focus on expanding into emerging countries.

### Key strategies adopted by companies within the Dipeptide Peptidase 4 Inhibitors industry

Leading Dipeptide Peptidase 4 Inhibitors companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Dipeptide Peptidase 4 Inhibitors companies.

## Dipeptide Peptidase 4 Inhibitors Market Study- Strategic Analysis Review

The Dipeptide Peptidase 4 Inhibitors market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-

**Industry Dynamics:** Porter's Five Forces analysis to understand bargaining power, competitive rivalry, and threats that impact long-term strategy formulation.

**Strategic Insights:** Provides valuable perspectives on key players and their approaches based on comprehensive strategy analysis.

**Internal Strengths and Weaknesses:** Develop targeted strategies to leverage strengths, address weaknesses, and capitalize on market opportunities.

**Future Possibilities:** Prepare for diverse outcomes with in-depth scenario analysis. Explore potential market disruptions, technology advancements, and economic changes.

## Dipeptide Peptidase 4 Inhibitors Market Size Outlook- Historic and Forecast Revenue in Three Cases

The Dipeptide Peptidase 4 Inhibitors industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2030 in three case scenarios- low case, reference case, and high case scenarios.

## Dipeptide Peptidase 4 Inhibitors Country Analysis and Revenue Outlook to 2030

The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2030. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2030.

## North America Dipeptide Peptidase 4 Inhibitors Market Size Outlook- Companies plan for focused investments in a changing environment

The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong end-user industry demand. Leading companies focus on new product launches in the changing environment. The US economy is expected to grow in 2024 (around 2.2% growth in 2024), potentially driving demand for various Dipeptide Peptidase 4 Inhibitors market segments. Similarly, Strong end-user demand is encouraging Canadian Dipeptide Peptidase 4 Inhibitors companies to invest in niche segments. Further, as Mexico continues to strengthen its trade relations and invest in technological advancements, the Mexico Dipeptide Peptidase 4 Inhibitors market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.

Europe Dipeptide Peptidase 4 Inhibitors Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities

The German industry remains the major market for companies in the European Dipeptide Peptidase 4 Inhibitors industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of businesses in identifying and leveraging new growth prospects positions the European Dipeptide Peptidase 4 Inhibitors market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.

Asia Pacific Dipeptide Peptidase 4 Inhibitors Market Size Outlook- an attractive hub for opportunities for both local and global companies

The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Dipeptide Peptidase 4 Inhibitors in Asia Pacific. In particular, China, India, and South East Asian Dipeptide Peptidase 4 Inhibitors markets present a compelling outlook for 2030, acting as a magnet for both domestic and multinational manufacturers seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major markets in the region.

Latin America Dipeptide Peptidase 4 Inhibitors Market Size Outlook- Continued urbanization and rising income levels

Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.

Middle East and Africa Dipeptide Peptidase 4 Inhibitors Market Size Outlook- continues its upward trajectory across segments

Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Dipeptide Peptidase 4 Inhibitors market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Dipeptide Peptidase 4 Inhibitors.

Dipeptide Peptidase 4 Inhibitors Market Company Profiles

The global Dipeptide Peptidase 4 Inhibitors market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are Merck And Co., AstraZeneca, Takeda Pharmaceuticals, Novartis

Recent Dipeptide Peptidase 4 Inhibitors Market Developments

The global Dipeptide Peptidase 4 Inhibitors market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.

Dipeptide Peptidase 4 Inhibitors Market Report Scope

Parameters: Revenue, Volume Price

Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2030 (Forecast Period)

Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)

## Qualitative Analysis

Pricing Analysis

Value Chain Analysis

SWOT Profile

Market Dynamics- Trends, Drivers, Challenges

Porter's Five Forces Analysis

Macroeconomic Impact Analysis

Case Scenarios- Low, Base, High

## Market Segmentation:

### By Drugs

Januvia (Sitagliptin)

Onglyza (Saxagliptin)

Tradjenta (Linagliptin)

Vipidia (Alogliptin)

Galvus (Vildagliptin)

Others

## Geographical Segmentation:

North America (3 markets)

Europe (6 markets)

Asia Pacific (6 markets)

Latin America (3 markets)

Middle East Africa (5 markets)

Companies

Merck And Co.

AstraZeneca

Takeda Pharmaceuticals

Novartis

Formats Available: Excel, PDF, and PPT

## Contents

### 1. EXECUTIVE SUMMARY

- 1.1 Dipeptide Peptidase 4 Inhibitors Market Overview and Key Findings, 2024
- 1.2 Dipeptide Peptidase 4 Inhibitors Market Size and Growth Outlook, 2021- 2030
- 1.3 Dipeptide Peptidase 4 Inhibitors Market Growth Opportunities to 2030
- 1.4 Key Dipeptide Peptidase 4 Inhibitors Market Trends and Challenges
  - 1.4.1 Dipeptide Peptidase 4 Inhibitors Market Drivers and Trends
  - 1.4.2 Dipeptide Peptidase 4 Inhibitors Market Challenges
- 1.5 Competitive Landscape and Key Players
- 1.6 Competitive Analysis- Growth Strategies Adopted by Leading Dipeptide Peptidase 4 Inhibitors Companies

### 2. DIPEPTIDE PEPTIDASE 4 INHIBITORS MARKET SIZE OUTLOOK TO 2030

- 2.1 Dipeptide Peptidase 4 Inhibitors Market Size Outlook, USD Million, 2021- 2030
- 2.2 Dipeptide Peptidase 4 Inhibitors Incremental Market Growth Outlook, %, 2021- 2030
- 2.3 Segment Snapshot, 2024

### 3. DIPEPTIDE PEPTIDASE 4 INHIBITORS MARKET- STRATEGIC ANALYSIS REVIEW

- 3.1 Porter's Five Forces Analysis
  - \* Threat of New Entrants
  - \* Threat of Substitutes
  - \* Intensity of Competitive Rivalry
  - \* Bargaining Power of Buyers
  - \* Bargaining Power of Suppliers
- 3.2 Value Chain Analysis
- 3.3 SWOT Analysis

### 4. DIPEPTIDE PEPTIDASE 4 INHIBITORS MARKET SEGMENTATION ANALYSIS AND OUTLOOK

- 4.1 Market Segmentation and Scope
- 4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030
  - By Drugs
    - Januvia (Sitagliptin)



Onglyza (Saxagliptin)

Tradjenta (Linagliptin)

Vipidia (Alogliptin)

Galvus (Vildagliptin)

Others

4.3 Growth Prospects and Niche Opportunities, 2023- 2030

4.4 Regional comparison of Market Growth, CAGR, 2023-2030

## **5. REGION-WISE MARKET OUTLOOK TO 2030**

5.1 Key Findings for Asia Pacific Dipeptide Peptidase 4 Inhibitors Market, 2025

5.2 Asia Pacific Dipeptide Peptidase 4 Inhibitors Market Size Outlook by Type, 2021-2030

5.3 Asia Pacific Dipeptide Peptidase 4 Inhibitors Market Size Outlook by Application, 2021- 2030

5.4 Key Findings for Europe Dipeptide Peptidase 4 Inhibitors Market, 2025

5.5 Europe Dipeptide Peptidase 4 Inhibitors Market Size Outlook by Type, 2021- 2030

5.6 Europe Dipeptide Peptidase 4 Inhibitors Market Size Outlook by Application, 2021-2030

5.7 Key Findings for North America Dipeptide Peptidase 4 Inhibitors Market, 2025

5.8 North America Dipeptide Peptidase 4 Inhibitors Market Size Outlook by Type, 2021-2030

5.9 North America Dipeptide Peptidase 4 Inhibitors Market Size Outlook by Application, 2021- 2030

5.10 Key Findings for South America Dipeptide Peptidase 4 Inhibitors Market, 2025

5.11 South America Pacific Dipeptide Peptidase 4 Inhibitors Market Size Outlook by Type, 2021- 2030

5.12 South America Dipeptide Peptidase 4 Inhibitors Market Size Outlook by Application, 2021- 2030

5.13 Key Findings for Middle East and Africa Dipeptide Peptidase 4 Inhibitors Market, 2025

5.14 Middle East Africa Dipeptide Peptidase 4 Inhibitors Market Size Outlook by Type, 2021- 2030

5.15 Middle East Africa Dipeptide Peptidase 4 Inhibitors Market Size Outlook by Application, 2021- 2030

## **6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030**

6.1 US Dipeptide Peptidase 4 Inhibitors Market Size Outlook and Revenue Growth

## Forecasts

- 6.2 US Dipeptide Peptidase 4 Inhibitors Industry Drivers and Opportunities
- 6.3 Canada Market Size Outlook and Revenue Growth Forecasts
- 6.4 Canada Dipeptide Peptidase 4 Inhibitors Industry Drivers and Opportunities
- 6.6 Mexico Market Size Outlook and Revenue Growth Forecasts
- 6.6 Mexico Dipeptide Peptidase 4 Inhibitors Industry Drivers and Opportunities
- 6.7 Germany Market Size Outlook and Revenue Growth Forecasts
- 6.8 Germany Dipeptide Peptidase 4 Inhibitors Industry Drivers and Opportunities
- 6.9 France Market Size Outlook and Revenue Growth Forecasts
- 6.10 France Dipeptide Peptidase 4 Inhibitors Industry Drivers and Opportunities
- 6.11 UK Market Size Outlook and Revenue Growth Forecasts
- 6.12 UK Dipeptide Peptidase 4 Inhibitors Industry Drivers and Opportunities
- 6.13 Spain Market Size Outlook and Revenue Growth Forecasts
- 6.14 Spain Dipeptide Peptidase 4 Inhibitors Industry Drivers and Opportunities
- 6.16 Italy Market Size Outlook and Revenue Growth Forecasts
- 6.16 Italy Dipeptide Peptidase 4 Inhibitors Industry Drivers and Opportunities
- 6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts
- 6.18 Rest of Europe Dipeptide Peptidase 4 Inhibitors Industry Drivers and Opportunities
- 6.19 China Market Size Outlook and Revenue Growth Forecasts
- 6.20 China Dipeptide Peptidase 4 Inhibitors Industry Drivers and Opportunities
- 6.21 India Market Size Outlook and Revenue Growth Forecasts
- 6.22 India Dipeptide Peptidase 4 Inhibitors Industry Drivers and Opportunities
- 6.23 Japan Market Size Outlook and Revenue Growth Forecasts
- 6.24 Japan Dipeptide Peptidase 4 Inhibitors Industry Drivers and Opportunities
- 6.26 South Korea Market Size Outlook and Revenue Growth Forecasts
- 6.26 South Korea Dipeptide Peptidase 4 Inhibitors Industry Drivers and Opportunities
- 6.27 Australia Market Size Outlook and Revenue Growth Forecasts
- 6.28 Australia Dipeptide Peptidase 4 Inhibitors Industry Drivers and Opportunities
- 6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts
- 6.30 South East Asia Dipeptide Peptidase 4 Inhibitors Industry Drivers and Opportunities
- 6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts
- 6.32 Rest of Asia Pacific Dipeptide Peptidase 4 Inhibitors Industry Drivers and Opportunities
- 6.33 Brazil Market Size Outlook and Revenue Growth Forecasts
- 6.34 Brazil Dipeptide Peptidase 4 Inhibitors Industry Drivers and Opportunities
- 6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
- 6.36 Argentina Dipeptide Peptidase 4 Inhibitors Industry Drivers and Opportunities
- 6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts

6.38 Rest of South America Dipeptide Peptidase 4 Inhibitors Industry Drivers and Opportunities

6.39 Middle East Market Size Outlook and Revenue Growth Forecasts

6.40 Middle East Dipeptide Peptidase 4 Inhibitors Industry Drivers and Opportunities

6.41 Africa Market Size Outlook and Revenue Growth Forecasts

6.42 Africa Dipeptide Peptidase 4 Inhibitors Industry Drivers and Opportunities

## **7. DIPEPTIDE PEPTIDASE 4 INHIBITORS MARKET OUTLOOK ACROSS SCENARIOS**

7.1 Low Growth Case

7.2 Reference Growth Case

7.3 High Growth Case

## **8. DIPEPTIDE PEPTIDASE 4 INHIBITORS COMPANY PROFILES**

8.1 Profiles of Leading Dipeptide Peptidase 4 Inhibitors Companies in the Market

8.2 Business Descriptions, SWOT Analysis, and Growth Strategies

8.3 Financial Performance and Key Metrics

Merck And Co.

AstraZeneca

Takeda Pharmaceuticals

Novartis

## **9. APPENDIX**

9.1 Scope of the Report

9.2 Research Methodology and Data Sources

9.3 Glossary of Terms

9.4 Market Definitions

9.5 Contact Information

## I would like to order

Product name: Dipeptide Peptidase 4 Inhibitors Market Size, Trends, Analysis, and Outlook By Drugs (Januvia (Sitagliptin), Onglyza (Saxagliptin), Tradjenta (Linagliptin), Vipidia (Alogliptin), Galvus (Vildagliptin), Others), by Region, Country, Segment, and Companies, 2024-2030

Product link: <https://marketpublishers.com/r/DD60F85057BBEN.html>

Price: US\$ 3,980.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/DD60F85057BBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970